Alexion Pharmaceuticals, Inc. and Synageva BioPharma Corp. announced today that they have entered into a definitive agreement pursuant to which Alexion will acquire Synageva for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva…
The $226 figure, which is based on yesterday’s closing price of ALXN, is a 136% premium to GEVA’s closing price yesterday. The nominal deal value is $8.4B.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.